Precision Cancer Vaccine
Cancer (specific type(s) not specified)
Phase 1Planned (FIH trial initiation targeted for end of 2024)
Key Facts
Indication
Cancer (specific type(s) not specified)
Phase
Phase 1
Status
Planned (FIH trial initiation targeted for end of 2024)
Company
About Infinitopes
Infinitopes is an Oxford University spin-out developing a next-generation cancer vaccine platform, termed Precision Immunomics™. The company combines a proprietary antigen discovery engine, which uses laboratory, computational, and machine learning workflows to identify optimal tumor targets, with a novel vector platform designed to induce potent and durable T-cell immunity. With a team experienced in over 70 oncology clinical trials, Infinitopes is accelerating towards a Phase I/IIa trial by the end of 2024, aiming to integrate its vaccines with standard care to improve patient outcomes.
View full company profile